31 Mar Cellectar cancer drug to be studied at UW American Family Children’s Hospital
An experimental cancer drug developed by Cellectar Biosciences, which has operations in Middleton and in New Jersey, will be studied on children and adolescents with a variety of solid tumors at UW Health’s American Family Children’s Hospital.
The drug, CLR131, delivers targeted high doses of radioactive iodine to cancer cells to kill them. A phase 1 trial, by UW Carbone Cancer Center, will begin only at UW and later include other children’s hospitals.
Dr. Mario Otto, co-principal investigator and an associate professor of pediatrics at UW-Madison, has found that in the test tube, a fluorescently labeled variant of the drug was concentrated in cancer-cell lines to a much greater extent than in healthy, normal cells, according to a statement. CLR 131 also showed efficacy in several models in which mice were implanted with various pediatric cancers.
Sorry, the comment form is closed at this time.